Integrated Filing — IndAS



General information about company

Scrip Code 532300
NSE Symbol WOCKPHARMA
MSEI Symbol NOTLISTED
ISIN INE049B01025
Name of company Wockhardt Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 10-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 10-08-2026   13:10:00
End date and time of board meeting 10-08-2026   15:05:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable as there is no default on loans and the company has no outstanding debt securities as on 30.06.2026



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 56,100.00 56,100.00
Other income 3,300.00 3,300.00
Total income 59,400.00 59,400.00
2 Expenses
(a) Cost of materials consumed 10,600.00 10,600.00
(b) Purchases of stock-in-trade 5,700.00 5,700.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 8.00 8.00
(d) Employee benefit expense 8,500.00 8,500.00
(e) Finance costs 4,300.00 4,300.00
(f) Depreciation, depletion and amortisation expense 4,100.00 4,100.00
(f) Other Expenses
1 Other Expenses 15,500.00 15,500.00
2 Rounding off (8.00) (8.00)
Total other expenses 15,492.00 15,492.00
Total expenses 48,700.00 48,700.00
3 Total profit before exceptional items and tax 10,700.00 10,700.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 10,700.00 10,700.00
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 0.00 0.00
9 Total tax expenses 0.00 0.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 10,700.00 10,700.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 10,700.00 10,700.00
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 10,700.00 10,700.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 8,100.00 8,100.00
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 6.62 6.62
Diluted earnings (loss) per share from continuing operations 6.61 6.61
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 6.62 6.62
Diluted earnings (loss) per share from continuing and discontinued operations 6.61 6.61
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1)The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The results have been subjected to limited review by the Statutory Auditors of the Company. 2)Figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures of the full financial year and the reviewed published figures upto the third quarter of financial year 2025-26. 3)The Company is exclusively into Pharmaceutical business Segment.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to Profit or Loss - credit/(charge) (consisting of re-measurement of net defined benefit liability) 8.00 8.00
2 Rounding Off (8.00) (8.00)
Total Amount of items that will not be reclassified to profit and loss 0.00
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.00 0.00





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 11-11-2024
Amount Raised 1,00,000.00
Report filed for Quarter ended 30-06-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment and/or pre-payment, in full or part, of certain borrowings availed by our Company. NO 50,000.00 0.00 50,000.00 0.00
2 Funding in capital expenditure, investment in research and development and incidental expenses. NO 25,000.00 0.00 11,130.00 0.00 In view of business exigencies and ongoing project timelines, the period for utilisation of the issue proceeds has been reviewed and extended by the Board upto financial year 2028 vide its resolution dated 4th May 2026.
3 General Corporate Purpose NO 22,397.00 22,779.00 22,779.00 0.00 During the quarter ended June 30, 2025, net proceeds have been revised from Rs 973.97 crores to Rs 977.79 crores, on account of actual issue expenses being lower than estimated as disclosed in the Offer Document, by Rs 3.82 crores and the same has been adjusted with Object 3: General Corporate Purposes.


Signatory Details

Name of signatory Rashmi Mamtura
Designation of person Company Secretary and Compliance Officer
Place Mumbai
Date 10-08-2026